These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32796009)

  • 1. Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data.
    Leal J; Reed SD; Patel R; Rivero-Arias O; Li Y; Schulman KA; Califf RM; Holman RR; Gray AM
    Diabetes Care; 2020 Oct; 43(10):2485-2492. PubMed ID: 32796009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of a Short Message Service Intervention to Prevent Type 2 Diabetes from Impaired Glucose Tolerance.
    Wong CK; Jiao FF; Siu SC; Fung CS; Fong DY; Wong KW; Yu EY; Lo YY; Lam CL
    J Diabetes Res; 2016; 2016():1219581. PubMed ID: 26798647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
    Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review.
    Zhou X; Siegel KR; Ng BP; Jawanda S; Proia KK; Zhang X; Albright AL; Zhang P
    Diabetes Care; 2020 Jul; 43(7):1593-1616. PubMed ID: 33534726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
    Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
    Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design.
    Sun X; Guo L; Shang H; Ren M; Wang Y; Huo D; Lei X; Wang H; Zhai J
    Trials; 2015 Nov; 16():496. PubMed ID: 26530718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD
    JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention.
    JAMA; 1998 Nov; 280(20):1757-63. PubMed ID: 9842951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained.
    Olchanski N; van Klaveren D; Cohen JT; Wong JB; Ruthazer R; Kent DM
    Acta Diabetol; 2021 Jun; 58(6):707-722. PubMed ID: 33517494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
    Eddy DM; Schlessinger L; Kahn R
    Ann Intern Med; 2005 Aug; 143(4):251-64. PubMed ID: 16103469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
    Harumi Higuchi Dos Santos M; Sharma A; Sun JL; Pieper K; McMurray JJ; Holman RR; Lopes RD
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28087508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.
    de Vries FM; Denig P; Visser ST; Hak E; Postma MJ
    Value Health; 2014 Mar; 17(2):223-30. PubMed ID: 24636380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes.
    Li T; Wan X; Ma J; Wu B
    Adv Ther; 2018 Dec; 35(12):2214-2223. PubMed ID: 30390239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary prevention of type 2 diabetes.
    American Association of Diabetes Educators
    Diabetes Educ; 2012; 38(1):147-50. PubMed ID: 22328043
    [No Abstract]   [Full Text] [Related]  

  • 17. A simulation model estimates lifetime health and economic outcomes of screening prediabetes using the 1-h plasma glucose.
    Andellini M; Manco M; Esposito MT; Tozzi AE; Bergman M; Ritrovato M
    Acta Diabetol; 2023 Jan; 60(1):9-17. PubMed ID: 36127565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care.
    Bertram MY; Lim SS; Barendregt JJ; Vos T
    Diabetologia; 2010 May; 53(5):875-81. PubMed ID: 20135088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of lifestyle changes on adults with prediabetes: A systematic review and meta-analysis.
    Glechner A; Keuchel L; Affengruber L; Titscher V; Sommer I; Matyas N; Wagner G; Kien C; Klerings I; Gartlehner G
    Prim Care Diabetes; 2018 Oct; 12(5):393-408. PubMed ID: 30076075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.